Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed: 20,548
Companies: 1,769
Drugs tracked: 4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources

Quick answer

First-in-human Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of the Adjuvanted Universal Influenza Vaccine “fH1/DSP-0546LP” in Healthy Adults

First-in-human Study to Test Safety and Anti-tumor Activity of a Novel Drug for Patients with Advanced Solid Tumor Harboring Genetic Alterations in MET

First-in-human Trial of DS-2243a in Participants with Advanced Solid Tumors

First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)

First-line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer (ES SCLC) (DeLLphi-303)

GK01 Injection

GMCN-508B (LentiRed)

GPC3 and/or TGFβ targeting CAR-T cells

GPRC5D CAR-T cell intravenous infusion

GST-HG121 tablets

Gallium-68 NODAGA-JR11

HER2 Tumor Vaccine

HSK3486

HSK3486

HY-2003 (10 mg/ml), BELKYRA and placebo

Hema-NeoTIL01

Human BCMA targeted T Cells Injection

Human Umbilical Mesenchymal Stem Cells

Human amniotic-derived mesenchymal stem cells

Hydronidone capsules

IBR733 Cell Injection

ICI201

JWCAR129

JY306 universal NK cell injection

Frequently asked questions